^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Estrogen receptor modulator

    Related drugs:
    3ms
    Employing cancer driver genes for the identification of immunological features in two esophageal cancer subtypes to facilitate immunotherapy. (PubMed, Immunopharmacol Immunotoxicol)
    Additionally, potential small-molecule drugs targeting DEGs in ESCA were investigated, such as 3,3'-diindolylmethane, SJ-172550, aminoglutethimide, nitrazepam, actarit, and epigallocatechin. The results of qRT-PCR showed that RUNX1, NONO, and TSC2 were not only significantly associated with the survival of esophageal squamous cell carcinoma (ESCC) but also significantly overexpressed in the ESCC cell lines (KYSE150 and KYSE450). This study is valuable for elucidating CDG functions in ESCA and for biomarker identification.
    Journal • IO biomarker
    |
    RUNX1 (RUNX Family Transcription Factor 1) • TSC2 (TSC complex subunit 2)
    |
    BR-DIM (oral microencapsulated diindolylmethane)
    3ms
    Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for Men with Schizophrenia (ACTRN12619001471178)
    P2, N=100, Recruiting, Monash University Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (Pueraria lobata). (PubMed, J Nat Prod)
    Tuberosin-treated endothelial cells suppressed vascular network assembly and maturation without affecting the cellular proliferative capacity. The presented studies leverage current kudzu management methods to naturally produce tuberosin, examine cell-type-specific effects, and support further investigation as an antiestrogen for breast cancer treatment.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    5ms
    Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=19, Suspended, Stanford University | Active, not recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Piqray (alpelisib) • fulvestrant • zotatifin (eFT226) • Soltamox (tamoxifen citrate)
    5ms
    HOLTER CO-PRE: Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational Study (clinicaltrials.gov)
    P=N/A, N=96, Recruiting, Ospedale Policlinico San Martino
    New trial
    7ms
    Precise structure manipulation of selective estrogen receptor modulators led to first-in-class thiophene-3-benzamide derivatives as potential ER-antagonists without uterotrophic activity. (PubMed, Bioorg Chem)
    In the dose-response experiment, the 5d antiestrogenic potency (EC50 = 5.530 μM) was comparable to that of Tamoxifen (EC50 = 7.625 μM). Molecular Docking and Molecular Dynamics simulations elucidated the antiestrogenic activity of 5d and inactivity of 5-fluorobenzoyl counterpart, 5e. The inactive derivative 5e in the active site exhibited an unfavorable conformation and unstable drug-receptor complex formation.
    Journal
    |
    ER (Estrogen receptor)
    |
    tamoxifen
    7ms
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    10ms
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (clinicaltrials.gov)
    P2, N=74, Not yet recruiting, University of Chicago | Initiation date: Jan 2025 --> Jan 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    11ms
    MCN_Tam: Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (clinicaltrials.gov)
    P1, N=15, Recruiting, University of Nebraska | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Soltamox (tamoxifen citrate)
    11ms
    A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=204, Not yet recruiting, Hinova Pharmaceuticals Inc.
    New P1/2 trial
    |
    Ibrance (palbociclib)
    11ms
    Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer (clinicaltrials.gov)
    P=N/A, N=31, Terminated, Albert Einstein College of Medicine | N=132 --> 31 | Active, not recruiting --> Terminated; Interventional component of study terminated prior to full enrollment
    Enrollment change • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • letrozole • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • Soltamox (tamoxifen citrate)
    12ms
    Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast (clinicaltrials.gov)
    P2, N=100, Completed, Northwestern University | Recruiting --> Completed | Phase classification: P2b --> P2
    Trial completion • Phase classification
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    afimoxifene • Soltamox (tamoxifen citrate)